Lonza Group (LTS:0QNO) ROCE % : 6.19% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Lonza Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lonza Group's annualized ROCE % for the quarter that ended in Jun. 2024 was 6.19%.

Lonza Group ROCE % Historical Data

The historical data trend for Lonza Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lonza Group ROCE % Chart

Lonza Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.99

7.77

6.59

10.65

6.23

Lonza Group Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															8.88	12.47	7.20	4.92	6.19

Lonza Group ROCE % Calculation

Lonza Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	883	/	( ( (17356 - 3080)	+	(16848 - 2763) )	/ 2 )
	=	883	/	( (14276	+	14085)	/ 2 )
	=	883	/	14180.5
	=	6.23 %

Lonza Group's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	908	/	( ( (16848 - 2763)	+	(17884 - 2609) )	/ 2 )
	=	908	/	( ( 14085	+	15275 )	/ 2 )
	=	908	/	14680
	=	6.19 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Lonza Group (LTS:0QNO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lonza Group ROCE % Related Terms

Thank you for viewing the detailed overview of Lonza Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lonza Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lonza Group Ltd (LTS:0QNO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LZAGY:USA LZAGF:USA LONN:Mexico LONNz:UK LO3A:Germany LONNE:Switzerland LONN:Switzerland

Address

Muenchensteinerstrasse 38, Basel, CHE, CH-4002

Website

https://www.lonza.com

Lonza Group is a contract development and manufacturing organization, or CDMO. It operates under four segments: small molecules, biologics, cell & gene, and capsules & health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing services throughout the entire lifecycle of a product from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.

Lonza Group Headlines

No Headlines